{"schema_version":"1","generated_at":"2026-11-03T01:43:23.652Z","data_as_of":null,"url":"https://www.findmykol.com/kol/naomi-fujioka","json_url":"https://www.findmykol.com/kol/naomi-fujioka/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"naomi-fujioka","name":"Naomi Fujioka","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"University of Minnesota","institution_url":"https://www.findmykol.com/institution/university-of-minnesota","city":"Minneapolis","state":"MN","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1881736833","orcid":"0000-0003-3277-6754","openalex":"A5044480763"},"summary":"Naomi Fujioka is an Oncology physician affiliated with University of Minnesota. OpenAlex indexes 73 publications with 911 citations (h-index 16); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":73,"cited_by_count":911,"h_index":16,"latest_activity_year":2025,"source":"works"},"trials":{"count":1,"shown":3,"withheld":1,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT03687073","title":"Trial of Indole-3-Carbinol and Silibinin","phase":"PHASE1","status":"COMPLETED","role":"Overall official","sponsor":"Masonic Cancer Center, University of Minnesota","source_url":"https://clinicaltrials.gov/study/NCT03687073","trial_url":"https://www.findmykol.com/trial/NCT03687073"},{"nct":"NCT02999399","title":"Glucobrassicin-Brussel Sprout Effect on D10 Phe Metabolism","phase":"PHASE1","status":"COMPLETED","role":"Overall official","sponsor":"Masonic Cancer Center, University of Minnesota","source_url":"https://clinicaltrials.gov/study/NCT02999399","trial_url":"https://www.findmykol.com/trial/NCT02999399"},{"nct":"NCT02845414","title":"Study of CD133KDEL Toxin in the Treatment for Solid Tumors","phase":"PHASE1","status":"WITHDRAWN","role":"Overall official","sponsor":"Masonic Cancer Center, University of Minnesota","source_url":"https://clinicaltrials.gov/study/NCT02845414","trial_url":"https://www.findmykol.com/trial/NCT02845414"}],"source":"trials"},"payments":{"company_count":2,"program_years":{"first":2021,"last":null},"rows_total":2,"shown":2,"withheld":0,"rows":[{"payer":"Merck Sharp & Dohme LLC","program_year":2024,"amount_usd":18.09,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1881736833"},{"payer":"Takeda Pharmaceuticals U.S.A., Inc.","program_year":2021,"amount_usd":2970,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1881736833"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1881736833","source":"payments"},"prescribing":{"data_year":2024,"areas_total":7,"areas_shown":3,"areas":[{"area":"Nervous system","share_pct":30.5,"classes_total":3,"classes":[{"class":"Phenothiazine","setting":"prescribed","share_pct":14.5,"drugs":[{"name":"Prochlorperazine Maleate","share_pct":100}],"max_beneficiaries":29},{"class":"Opioid Agonist","setting":"prescribed","share_pct":9,"drugs":[{"name":"Oxycodone Hcl","share_pct":100}],"max_beneficiaries":14}]},{"area":"Metabolism & gastrointestinal","share_pct":22.7,"classes_total":3,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":12.9,"drugs":[{"name":"Ondansetron Hcl","share_pct":100}],"max_beneficiaries":22},{"class":"Corticosteroid","setting":"prescribed","share_pct":5.5,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":11}]},{"area":"Hormonal (systemic)","share_pct":14.8,"classes_total":1,"classes":[{"class":"l-Thyroxine","setting":"prescribed","share_pct":14.8,"drugs":[{"name":"Levothyroxine Sodium","share_pct":100}],"max_beneficiaries":16}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":34.1,"facility_pct":65.9},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancer","year":2025,"journal":"Journal for ImmunoTherapy of Cancer","source_url":"https://doi.org/10.1136/jitc-2024-011370","status":"verified"},{"title":"Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081","year":2025,"journal":"Journal for ImmunoTherapy of Cancer","source_url":"https://doi.org/10.1136/jitc-2024-010316","status":"verified"},{"title":"Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study","year":2025,"journal":"European Journal of Cancer","source_url":"https://doi.org/10.1016/j.ejca.2025.115603","status":"verified"},{"title":"Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study","year":2024,"journal":"Lung Cancer","source_url":"https://doi.org/10.1016/j.lungcan.2024.107932","status":"verified"},{"title":"One-Week Kava Dietary Supplementation Increases Both Urinary <i>N</i>- and <i>O</i>-Glucuronides of NNAL, a Lung Carcinogen Major Metabolite, among Smokers","year":2024,"journal":"Chemical Research in Toxicology","source_url":"https://doi.org/10.1021/acs.chemrestox.4c00109","status":"verified"}],"source":"works"},"contact":{"address_1":"909 FULTON ST SE","city":"Minneapolis","state":"MN","zip":"554554800","phone":"612-625-3600","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1881736833","source":"identity"},"similar":[{"name":"Jay Cohn","slug":"jay-cohn","institution":"University of Minnesota","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/jay-cohn","json_url":"https://www.findmykol.com/kol/jay-cohn/profile.json"},{"name":"Douglas Yee","slug":"douglas-yee","institution":"University of Minnesota","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/douglas-yee","json_url":"https://www.findmykol.com/kol/douglas-yee/profile.json"},{"name":"David Benditt","slug":"david-benditt","institution":"University of Minnesota","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/david-benditt","json_url":"https://www.findmykol.com/kol/david-benditt/profile.json"},{"name":"Stuart Grossman","slug":"stuart-grossman","institution":"University of Minnesota","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/stuart-grossman","json_url":"https://www.findmykol.com/kol/stuart-grossman/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":1,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2024-01-18","provider_certified":"2024-01-18","collected_at":"2026-11-02T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}